1. MCP-1 and MIP-1α are Most Efficient in Recruiting T Cells into the SkinIn Vivo 
Rainer Kunstfeld, Sonja Lechleitner, Klaus Wolff, Peter Petzelbauer 
Journal of Investigative Dermatology 
Volume 111, Issue 6, Pages (December 1998)
DOI: /j x
Copyright © 1998 The Society for Investigative Dermatology, Inc Terms and Conditions

2. Figure 1
Time kinetics of T cell infiltrates following chemokine injection. A cocktail of rh MIP-1a, MCP-1, and RANTES, 200 ng each, was injected into the human skin sites 5, 7, or 9 d following grafting of human T cells into the peritoneal cavity. The skin specimens were harvested at indicated times following chemokine injection and numbers of T cells were counted in cryostat sections stained with an anti-CD3 monoclonal antibody as described inMaterials and Methods. SVP, superficial vascular plexus skin; DVP, deep vascular plexus skin. One of two experiments is shown.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 1998 The Society for Investigative Dermatology, Inc Terms and Conditions

3. Figure 2
MCP-1-induced T cell infiltrates are restricted to sites of human endothelium. MCP-1 (left panel) was injected into human skin, mouse skin, or mouse muscle 7 d following T cell engraftment, skin specimens were harvested 48 h following the intradermal MCP-1 injection, and numbers of T cells per high power field were enumerated; results of three independent experiments are shown. TNF was used as a positive control (right panel).
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 1998 The Society for Investigative Dermatology, Inc Terms and Conditions

4. Figure 3
Chemokine differences in attracting human T cells. Chemokines were injected at day 7 following T cell engraftment, human skin was harvested 48 h later. Results are shown as thex-fold increase in numbers of T cells in chemokine-injected skin sites compared with its individual solvent control. Logarithmic scale at they axis.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 1998 The Society for Investigative Dermatology, Inc Terms and Conditions

5. Figure 4
Chemokine-induced patterns of T cell inflammation. (a) Human deep vascular plexus skin 48 h following rh MCP-1 injection; all human vessels in red (UEA-1 staining) are surrounded by numerous human T cells in blue (anti-human CD3 staining, examples given byarrows). The insert in (a) shows human DVP skin 48 h following solvent control injection, human vessels in red are surrounded by single human T cells in blue (arrows). (b) Serial section of the skin specimen shown in (a); mouse vessels in red (anti-mouse CD31 staining,arrows) are not surrounded by human T cells in blue (anti-human CD3 staining). (c) Mouse muscle of the abdominal wall 48 h following rh IP-10 injection; human CD3 positive T cells (red) are attached to and within the peritoneum and between the muscle fibers; the peritoneal cavity is marked by an asterisk, counter staining with Mayer’s hematoxylin in blue. (d) Mouse muscle of the abdominal wall 48 h following solvent control injection, CD3-positive T cells stained in red are completely absent; the peritoneal cavity is marked by an asterisk, counter staining with Mayer’s hematoxylin in blue. (e) Mouse back skin 48 h following rh MCP-1 injection, UEA-1 (red) stains the mouse epidermis and mouse adnexial structures but not mouse vessels, CD3-positive human T cells (stained in blue) are completely absent. (f) Mouse gluteal muscle 48 h following rh MCP-1 injection, mouse vessels are stained in red (anti-mouse CD31), CD3-positive human T cells (stained in blue) are completely absent.Scale bar: 0.1 mm.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 1998 The Society for Investigative Dermatology, Inc Terms and Conditions

6. Figure 5
MCP-1-induced mRNA expression within human and mouse tissues. Forty-eight hours following MCP-1 or solvent control injection, mRNA was amplified by RT-PCR from 10 mg of human superficial vascular plexus skin (SVP) and deep vascular plexus skin (DVP), from mouse skin or from mouse gluteal muscle.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 1998 The Society for Investigative Dermatology, Inc Terms and Conditions